ABOUT US
At Cyberna, we strongly believe that the early detection of cancer at a subclinical stage
is the most effective form of therapy.
Our mission is to develop innovative, highly sensitive, and accessible screening tools for patients.
By enabling timely and accurate interventions, we aim to revolutionize cancer care and significantly improve the chances of successful treatment and recovery.
Our Products
Our approach involves developing epitranscriptomic (post-transcriptional chemical modifications of RNA) signatures through the identification and multivariate analysis of nucleoside biomarkers using mass spectrometry, combined with machine learning, from micro-blood samples.
We use mass spectrometry to detect unique epitranscriptomic signatures obtained through advanced artificial intelligence techniques (machine learning), from a drop of a patient’s blood. This allows us to identify cancer at its earliest stages.
The Team
The creation of « Cyberna » was, above all, the result of a remarkable human adventure that began in 2019 with the establishment of the first clinical platform for RNA chemistry analysis using mass spectrometry bringing together what would later become the founding multidisciplanry scientific team of this startup which has been associated an executive team with more than 20 years experiences in biotech and diagnostic industry to create Cyberna.
